Patients ( N = 443 ) with stage II to III TNBC received paclitaxel 80 mg/m ( 2 ) once per week ( wP ) for 12 weeks , followed by doxorubicin plus cyclophosphamide once every 2 weeks ( ddAC ) for four cycles , and were randomly assigned to concurrent carboplatin ( area under curve 6 ) once every 3 weeks for four cycles and/or bevacizumab 10 mg/kg once every 2 weeks for nine cycles .